🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Global Challenge

Cases of gonorrhoea are escalating worldwide, with estimates suggesting over 82 million new cases per year. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to develop it.

“This authorization signifies a significant shift in the management of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Outcomes and Worldwide Availability

Based on results detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which uses a dual-drug approach. The study included nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to make available and distribute the drug in many developing nations.

Clinicians treating patients have voiced hope. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for public health efforts. This is deemed essential to lessen the impact of the illness for individuals and to stop the proliferation of untreatable gonorrhoea globally.